Severe Acute Respiratory Syndrome Coronavirus 2
Coronavirus disease 2019 is a newly emerging infectious disease that is currently spreading globally. It is caused by a new type of coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The spike (S) protein of SARS-CoV-2 plays a key role in the process of receptor recognition and cell membrane fusion, and is composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain that recognizes and binds to the host receptor angiotensin converting enzyme 2, while the S2 subunit mediates viral cell membrane fusion by forming a six-helix bundle through two heptapeptide repeat domains. In this review, we focused on the latest research progress in the structure, function and development of antiviral drugs targeting S protein.
Human Anti-SARS-CoV-2(2019-nCoV) S2 Antibody (CAT#: MO-NAB-00881W)
-
- Host species: Human
- Species Reactivity: SARS-CoV-2; SARS-COV
- Application: WB, ELISA
- Conjugate: NONE
- Alternative Names: Anti Spike glycoprotein antibody, Anti Spike protein S2 antibody, Anti 2019-nCOV spike antibody, Anti-2019-nCOV RBD antibody, Anti S2 antibody
Human Anti-SARS-CoV-2(2019-nCoV) S2 Antibody (CAT#: MO-NAB-00914W)
-
- Host species: Human
- Species Reactivity: SARS-CoV-2; SARS-COV
- Application: WB, ELISA
- Conjugate: NONE
- Alternative Names: Anti Spike glycoprotein antibody, Anti Spike protein S2 antibody, Anti 2019-nCOV spike antibody, Anti-2019-nCOV RBD antibody, Anti S2 antibody
